Search the GHTC website

Global health R&D delivers for North Carolina

US government investment in global health R&D has delivered

$410.0 million
to North Carolina research institutions
5,900+ new jobs
for North Carolina
Global health R&D at work in North Carolina

RTI International, in partnership with TB Alliance, is supporting development of new drugs for tuberculosis. One new drug therapy, PaMZ, promises to dramatically shorten and simplify treatment for multidrug-resistant tuberculosis (MDR-TB). Today people with MDR-TB face up to two years of treatment with only a 50 percent success rate. This game-changing therapy now in late-stage development is expected to decrease treatment to 6 months and reduce costs by 90 percent.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: Flickr/Victor